Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 15, 2023
Reporting period
Not applicable
Filed with the SEC
Feb 27, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001231589-26-000005
Filed / recorded
Feb 27, 2026, 2:31 AM UTC
Added to OQRO
Oct 6, 2026, 9:34 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
UNITED THERAPEUTICS Corp
Issuer CIK
1082554
Ticker
UTHR
Reporting person
Paul A Mahon
Relationship
Officer
Officer title
EVP & GENERAL COUNSEL
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
Mar 15, 2023
Transaction code
A
Shares / units
8,895
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
8,895
Ownership form
Direct
Amendment
No
Footnotes from the filing
These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.
Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
Not applicable as restricted stock units do not have an expiration date.